Japan’s Ministry Approves Doxil For Ovarian Cancer
This article was originally published in PharmAsia News
Executive Summary
The Ministry of Health, Labor and Welfare Pharmaceutical Affairs Division March 30 approved Doxil (doxorubicin) for the additional indication of ovarian cancer in Japan. The approval came with a postmarket all-case surveillance condition as the Ministry cited lack of clinical data. Marketed in Japan by Janssen Pharmaceutical K.K, doxorubicin was previously approved for AIDS-related Kaposi's sarcoma in Japan. Japan's ovarian cancer patient groups petitioned the MHLW for the drug's approval. (Click here for more - Japanese language
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.